Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML-Reference-Cited by-同舟云学术

Physician risk perceptions and surveillance practices for tyrosine kinase inhibitor long-term effects in pediatric CML

Published:2021-12-17 Issue: Volume: Page:1-15
ISSN:0888-0018
Container-title:Pediatric Hematology and Oncology
language:en
Short-container-title:Pediatric Hematology and Oncology

Author:

Smith Stephanie M.¹^ORCID,Zhang Shiqi²,Sundaram Vandana²,Roth Michael³,Andolina Jeffrey R.⁴,Schapira Lidia⁵^ORCID,Sakamoto Kathleen M.¹,Kolb E. Anders⁶,Hijiya Nobuko⁷,Chaudhury Sonali⁸

Affiliation:

1. Department of Pediatrics, Division of Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, California, USA

2. Department of Medicine, Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, California, USA

3. Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4. Department of Pediatrics, Golisano Children’s Hospital, University of Rochester Medical Center, Rochester, New York, USA

5. Department of Medicine, Division of Oncology, Stanford Cancer Institute and Stanford University School of Medicine, Palo Alto, California, USA

6. Department of Pediatrics, Nemours/Alfred I. duPont Hospital for Children, Nemours Center for Cancer and Blood Disorders, Wilmington, Delaware, USA

7. Pediatric Hematology, Oncology, and Stem Cell Transplant, Columbia University Irving Medical Center, New York, New York, USA

8. Department of Pediatrics, Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Funder

Stanford Maternal and Child Health Research Institute

National Cancer Institute of the National Institutes of Health NCTN Operation Center

National Center for Advancing Translational Sciences, National Institutes of Health

Publisher

Informa UK Limited

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/08880018.2021.2017085

Reference32 articles.

1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2017, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, Published April 2020. Accessed 5/11/2021.

2. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: incidence—SEER 9 Regs Research Data, Nov 2020 Sub (1975-2018), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch. www.seer.cancer.gov. released April 2021, based on the November 2020 submission. Accessed 5/11/2021.

3. National Comprehensive Cancer Network Guidelines. Chronic myeloid leukemia (version 3.2021). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed May 5, 2021.

4. How I treat chronic myeloid leukemia in children and adolescents

5. Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. When should a Reduced intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HSCT) be Considered in Pediatric CML-CP1?;Transplantation and Cellular Therapy;2022-07

2. Distribution and frequency of tyrosine kinase inhibitor‐associated long‐term complications in children with chronic myeloid leukemia;Pediatric Blood & Cancer;2022-05-20